The study will assess the effectiveness of Pioglitazone on cellular and clinical levels in terms of improvement of both skin and systemic manifestations of psoriasis. The investigators assume that pioglitazone (one of thiazolidinediones readily available in Egypt), can regulate keratinocytes' disordered proliferation observed in psoriasis, in addition to improving the insulin resistance in peripheral tissues observed in many psoriatic patients and causing metabolic syndrome. This will allow to give a safer therapy than the available ones for psoriasis and to treat the patient in a more global perspective.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
48
pioglitazone 30 mg tablet , once daily dose for 10 weeks
one tablet of vehicle without active ingredient pioglitazone
Dermatology department of cairo university faculty of medicine
Cairo, Egypt
Treatment success detected as clinical improvement of skin condition
PASI improvement by at least 50% from baseline before treatment(Psoriasis Area and Severity Index)= PASI-50
Time frame: 10 weeks
Fasting serum insulin reduction from baseline before treatment
Time frame: 10 weeks
C-reactive protein titre reduction from baseline value before treatment
Time frame: 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.